LGM Pharma unveils enhanced analytical testing services and expands CDMO portfolio with additional suppository manufacturing capabilities

LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced a significant enhancement of its capabilities: a 50% expansion and an investment exceeding $2 million in its standalone offering for Analytical Testing Services (ATS) alongside the introduction of new suppository manufacturing capabilities to its contract development and manufacturing (CDMO) portfolio. These strategic enhancements provide additional internal bandwidth for growth while also providing customers greater flexibility with a streamlined, efficient, and comprehensive solution for their manufacturing needs.

Standalone analytical testing services

With a broad array of analytical testing capabilities for small-molecule drug substances and drug products, LGM Pharma can meet the demands of large and small clients, from established pharmaceutical companies to start-ups. In addition to analytical testing, the company provides comprehensive method development and validation services, as well as stability testing, including real-time and accelerated stability studies. LGM Pharma’s analytical laboratories, located at the CDMO’s facility in Irvine, California, are equipped with stateof-the-art chromatography and spectroscopy instrumentation, including ICP-MS and ICP-OES, to exceed the industry’s highest standards.

“Offering standalone analytical testing expands our agility and capacity to serve as a strategic resource for our pharmaceutical partners, providing them with flexibility to meet the precise needs of their expanding product portfolios,” said Prasad Raje, PhD, Chief Executive Officer at LGM Pharma. “With our continuum of robust and tailored support services, we enable pharmaceutical companies to get to market faster and achieve sustainable success in today’s complex market.”

We take a rigorous, multi-disciplinary approach to address our customers’ most complex analytical needs. Our team consists of more than 60 quality and analytical specialists who have decades of experience in all aspects of analytical testing, method development, and validation. We are proud of our excellent track record and our history of success supporting clients with the highest quality manufacturing and testing services.”

Shailesh Vengurlekar, Senior Vice President of Quality & Regulatory Affairs, LGM Pharma

Suppository formulation and manufacturing

As demand for suppositories gains significant traction, especially in the realm of women’s health products, LGM Pharma is expanding its manufacturing capacity at its facility in Rosenburg, Texas. This forward-looking investment aligns seamlessly with the organization’s commitment to meeting the diverse and growing demands of the pharmaceutical industry.

Suppository drug delivery systems enable more direct and efficient drug absorption for precise drug release kinetics, including for high medication concentrations and extended drug release times. They provide an excellent solution for patients with difficulty swallowing pills or those experiencing nausea, as well as for chronic conditions and women’s health.

“As patient needs become increasingly diversified, the pharmaceutical industry needs CDMO partners that can provide specialized capabilities,” said Ian Gibson, Executive Vice President of Operations at LGM Pharma. “Our expertise in suppository formulation development and manufacturing, including the most advanced delivery systems, represents another example of our dedication to providing strategic solutions to our industry partners.”

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    LGM Pharma. (2024, March 13). LGM Pharma unveils enhanced analytical testing services and expands CDMO portfolio with additional suppository manufacturing capabilities. News-Medical. Retrieved on May 24, 2024 from https://www.news-medical.net/news/20240313/LGM-Pharma-unveils-enhanced-analytical-testing-services-and-expands-CDMO-portfolio-with-additional-suppository-manufacturing-capabilities.aspx.

  • MLA

    LGM Pharma. "LGM Pharma unveils enhanced analytical testing services and expands CDMO portfolio with additional suppository manufacturing capabilities". News-Medical. 24 May 2024. <https://www.news-medical.net/news/20240313/LGM-Pharma-unveils-enhanced-analytical-testing-services-and-expands-CDMO-portfolio-with-additional-suppository-manufacturing-capabilities.aspx>.

  • Chicago

    LGM Pharma. "LGM Pharma unveils enhanced analytical testing services and expands CDMO portfolio with additional suppository manufacturing capabilities". News-Medical. https://www.news-medical.net/news/20240313/LGM-Pharma-unveils-enhanced-analytical-testing-services-and-expands-CDMO-portfolio-with-additional-suppository-manufacturing-capabilities.aspx. (accessed May 24, 2024).

  • Harvard

    LGM Pharma. 2024. LGM Pharma unveils enhanced analytical testing services and expands CDMO portfolio with additional suppository manufacturing capabilities. News-Medical, viewed 24 May 2024, https://www.news-medical.net/news/20240313/LGM-Pharma-unveils-enhanced-analytical-testing-services-and-expands-CDMO-portfolio-with-additional-suppository-manufacturing-capabilities.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.